에 대한 최신 뉴스 Cytokinetics (NASDAQ:CYTK) 주식

CYTOKINETICS INC

Cytokinetics

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight and lowers the price target from $71 to $53.

News

Price Target

Analyst Ratings

CYTK

JP Morgan Maintains Overweight on Cytokinetics, Lowers Price Target to $53

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform and lowers the price target from $103 to $84.

Mizuho Maintains Outperform on Cytokinetics, Lowers Price Target to $84

<ul>
<li>&nbsp;Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions</li>
<li>HEOR Analyses of Real-World Data Reveal Disparities in Outcomes In Females and Older Patients with Non-Obstructive HCM</li>
</ul>

Reported Sunday, Cytokinetics Presents New SEQUOIA-HCM Analyses at ESC Heart Failure 2025 Showing Consistent Aficamten Efficacy Across Symptom Severity And Regions

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Reiteration

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Investors with a lot of money to spend have taken a bearish stance on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CYTK, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Cytokinetics.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $63,138, and 7, calls, for a total amount of $1,105,300.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $50.0 for Cytokinetics over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Cytokinetics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Cytokinetics's whale activity within a strike price range from $30.0 to $50.0 in the last 30 days. 
<h3>Cytokinetics Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747166514_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$10.9</td>
<td>$9.1</td>
<td>$9.1</td>
<td>$40.00</td>
<td>$455.0K</td>
<td>3.8K</td>
<td>500</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$0.8</td>
<td>$0.5</td>
<td>$0.8</td>
<td>$50.00</td>
<td>$240.3K</td>
<td>5.0K</td>
<td>3.0K</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.2</td>
<td>$5.0</td>
<td>$5.0</td>
<td>$40.00</td>
<td>$175.0K</td>
<td>214</td>
<td>500</td>
</tr>
<tr>
<td>CYTK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$0.8</td>
<td>$0.5</td>
<td>$0.8</td>
<td>$50.00</td>
<td>$160.0K</td>
<td>5.0K</td>
<td>5.0K</td>
</tr>
<tr>
<td>CYTK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.9</td>
<td>$0.55</td>
<td>$1.9</td>
<td>$30.00</td>
<td>$63.1K</td>
<td>219</td>
<td>340</td>
</tr>
</tbody>
</table>

<h3>About Cytokinetics</h3>
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
In light of the recent options history for Cytokinetics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Cytokinetics</h3>
<ul>
<li>With a trading volume of 2,938,087, the price of CYTK is up by 0.84%, reaching $32.4.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 86 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Cytokinetics</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $73.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $120. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $72. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Cytokinetics, targeting a price of $41. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Cytokinetics, maintaining a target price of $53. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Cytokinetics, which currently sits at a price target of $80. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cytokinetics options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Cytokinetics Unusual Options Activity

Biotech

Health Care

General

Cytokinetics' MAPLE-HCM Phase 3 Trial Comparing Aficamten To The Standard Of Care Beta Blocker Metoprolol For Symptomatic Obstructive Hypertrophic Cardiomyopathy Met Its Primary Endpoint

Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Overweight and lowers the price target from $55 to $53.

Barclays Maintains Overweight on Cytokinetics, Lowers Price Target to $53

RBC Capital analyst Leonid Timashev maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Outperform and lowers the price target from $82 to $80.

RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $80

Citigroup analyst David Lebowitz maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and lowers the price target from $86 to $80.

Citigroup Maintains Buy on Cytokinetics, Lowers Price Target to $80

Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) reported quarterly losses of $(1.36) per share which beat the analyst consensus estimate of $(1.37) by 0.73 percent. This is a 2.26 percent decrease over losses of $(1.33) per share from the same period last year. The company reported quarterly sales of $1.58 million which beat the analyst consensus estimate of $1.20 million by 31.29 percent. This is a 89.10 percent increase over sales of $835.00 thousand the same period last year.

Earnings

Earnings Beats

Cytokinetics Q1 EPS $(1.36) Beats $(1.37) Estimate, Sales $1.58M Beat $1.20M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Neutral and lowers the price target from $47 to $41.

UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41

The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>)&nbsp;aficamten for patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26 <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">from September 26</a>.
The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Mitigation Strategy (REMS)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44903741/fda-eases-monitoring-requirements-for-bristol-myers-heart-drug-camzyos-analyst-sees-as-timely-boost-ahead-of-rivals-review" rel="noreferrer noopener">Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach</a>
Following pre-NDA discussions with the FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for&nbsp;aficamten in oHCM without an accompanying REMS, and the FDA <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45150594/cytokinetics-announces-new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy" rel="noreferrer noopener">accepted the NDA for filing</a>.
Recently, during the NDA review, the FDA requested that Cytokinetics submit a REMS, based on the inherent characteristics of&nbsp;aficamten, which the company provided.
The submission of a REMS has now been determined by FDA to be a Major Amendment to the NDA resulting in a standard three-month extension to the original PDUFA action date.
No additional clinical data or studies have been requested on Cytokinetics by the FDA.
"We remain confident in the distinct benefit-risk and pharmaceutic profile of&nbsp;aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential approval by FDA," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "
In April, Bristol Myers Squibb&nbsp;&amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) released topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos&nbsp;(mavacamten) for symptomatic New York Heart Association (NYHA) class II-III non-obstructive <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44825297/why-us-pharma-giant-bristol-myers-squibb-stock-trading-lower-on-tuesday" rel="noreferrer noopener">hypertrophic cardiomyopathy (nHCM)</a>.
The trial did not meet its dual primary endpoints of changes from baseline to Week 48 compared to placebo in the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) and peak oxygen&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44801468/bristol-myers-squibb-provides-update-on-phase-3-odyssey-hcm-trial" rel="noreferrer noopener">consumption (pVO2)</a>.
In January, a Stifel analyst wrote that Cytokinetics appears well-positioned to capitalize on Bristol Myers' groundwork with its second-to-market drug, Alicante, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms <a target="_blank" href="https://www.benzinga.com/25/01/43143013/analyst-optimistic-about-cytokinetics-heart-drugs-future-despite-ma-hurdles-and-royalty-deal-concerns" rel="noreferrer noopener">(Q6M echos) as a standard</a>.
Price Action: CYTK stock is down 16.5% at $35.85 at the last check Friday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-asthma" target="_blank" rel="noreferrer noopener">AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma</a></li>
</ul>

Large Cap

Movers

Trading Ideas

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Shares of Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/xyz/earnings">worse-than-expected first-quarter financial results.</a>
Block reported quarterly earnings of 56 cents per share, which missed market estimates of 87 cents per share. Quarterly revenue came in at $5.77 billion, missing the consensus estimate of $6.2 billion.
Block shares dipped 21.9% to $45.66 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Advantage Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) fell 18.9% to $1.07 in pre-market trading. Advantage Solutions will release financial results for the first quarter on May 12.</li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) dipped 16.4% to $4.57 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) declined 16% to $192.35 in pre-market trading after the company issued fourth-quarter sales guidance below estimates.</li>
<li>LendingTree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) fell 12.9% to $47.14 in pre-market trading after the company reported worse-than-expected first-quarter sales results, issued second-quarter sales guidance below estimates, and cut its FY25 sales guidance.</li>
<li>Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) dipped 12.1% to $37.71 in pre-market trading after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) dropped 6.4% to $63.00 in pre-market trading after the company issued FY25 sales guidance below estimates.</li>
<li>Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) fell 4.7% to $72.63 in pre-market trading as the company posted downbeat quarterly results and lowered its FY2025 earnings guidance.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 2.9% to $207.24 in today's pre-market trading. Apple reported fiscal second-quarter revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share. The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) fell 2.3% to $185.93 in pre-market trading. Amazon reported stronger-than-expected first-quarter financial results after market close Thursday. The company said it expects second-quarter net sales of $159 billion to $164 billion, up 7% to 11%. Analysts expect the company to have net sales of $160.91 billion in the quarter.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AAPL

AMZN

ARDX

ROKU

TEAM

TREE

Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday's Pre-Market Session

WIIM

Cytokinetics shares are trading lower after the company announced the FDA has extended the Prescription Drug User Fee Act action date for Aficamten.

<h3>Gainers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 42.3% to $1.11 during Thursday's after-market session. The company's market cap stands at $7.2 million. </li>
<li>SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) shares moved upwards by 18.46% to $12.8. The company's market cap stands at $2.4 billion. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock increased by 11.47% to $6.9. The company's market cap stands at $109.0 million. The company's, Q1 earnings came out today. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares rose 8.93% to $0.84. The market value of their outstanding shares is at $3.7 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares moved upwards by 8.77% to $51.3. The market value of their outstanding shares is at $9.6 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) shares increased by 8.76% to $4.22. The company's market cap stands at $69.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 14.4% to $4.68 during Thursday's after-market session. The company's market cap stands at $1.1 billion. As per the press release, Q1 earnings came out today. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares declined by 13.59% to $37.09. The company's market cap stands at $4.3 billion. </li>
<li>AN2 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTX#NASDAQ">ANTX</a>) stock fell 12.1% to $1.09. The company's market cap stands at $32.8 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock fell 11.12% to $0.16. The market value of their outstanding shares is at $4.6 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 11.12% to $0.24. The company's market cap stands at $10.8 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 9.53% to $0.38. The company's market cap stands at $10.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

AMWL

ANTX

EXAS

HCTI

ONMD

OWLT

SILO

SSII

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's After-Market Session

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) to December 26, 2025. The FDA recently notified Cytokinetics that additional time is required to conduct a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).
Following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS, and the FDA accepted the NDA for filing. Recently, during the NDA review, the FDA requested that Cytokinetics submit a REMS, based on the inherent characteristics of aficamten, which the company provided. The submission of a REMS has now been determined by FDA to be a Major Amendment to the NDA resulting in a standard three-month extension to the original PDUFA action date. No additional clinical data or studies have been requested of Cytokinetics by FDA.

Cytokinetics Announces The U.S. FDA Has Extended The Prescription Drug User Fee Act Action Date For The New Drug Application For Aficamten For The Treatment Of Patients With Obstructive Hypertrophic Cardiomyopathy To December 26, 2025

Cytokinetics shares are trading higher after Barclays initiated coverage on the stock with an Overweight rating and announced a price target of $55.

Press Releases

Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Comments

Cytokinetics

뉴스

에 대한 최신 뉴스 Cytokinetics (NASDAQ:CYTK) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌